Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.33 |
| ▸ | RAF1 | P04049 | 5/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838150 | 0.91 | GRM4 (0.35) | KDM4EALDH1A1ADAM17GRM4BTK | |
| SCHEMBL16195058 | 0.78 | BRAF (0.38) | BRAFRAF1CYP2C9 | |
| SCHEMBL16195352 | 0.77 | BRAF (0.33) | BRAFRAF1CYP2C9 | |
| SCHEMBL13734640 | 0.77 | BRAF (0.55) | BRAFRAF1GRM4CYP2C9 | |
| SCHEMBL13837919 | 0.68 | NPC1 (0.32) | — | |
| SCHEMBL13837918 | 0.67 | HDAC8 (0.36) | — | |
| SCHEMBL13736288 | 0.65 | BRAF (0.53) | BRAFRAF1CYP2C9 | |
| SCHEMBL13734662 | 0.65 | BRAF (0.53) | BRAFRAF1CYP2C9 | |
| SCHEMBL13734976 | 0.58 | BRAF (0.54) | BRAFRAF1CYP2C9 | |
| SCHEMBL122220 | 0.57 | NPC1 (0.46) | KDM4EALDH1A1ADAM17GRM4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | BRAF, RAF1, NRAS | BRAF 1/4885KDM4E 1762/4885ALDH1A1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.